| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
51,330,000 |
| Market
Cap: |
11.47(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.2235 - $0.2235 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile VYNE Therapeutics is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. Co.'s product candidate, FMX114, which is being evaluated for the potential treatment of mild-to-moderate atopic dermatitis. Co. is also in the preclinical stages of developing products containing Bromodomain and Extra-Terminal Domain (BET) inhibitor compounds. Co.'s initial BET inhibitor candidate in development is VYN201, an administered pan-BET inhibitor, which it is exploring in various immuno-inflammatory diseases, including skin diseases.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
13,000 |
13,000 |
43,000 |
| Total Buy Value |
$0 |
$50,778 |
$50,778 |
$125,458 |
| Total People Bought |
0 |
1 |
1 |
2 |
| Total Buy Transactions |
0 |
1 |
1 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Domzalski David |
President and CEO |
• • – |
2022-03-17 |
4 |
A |
$0.00 |
$0 |
D/D |
312,302 |
1,072,935 |
|
- |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2022-03-17 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
238,213 |
|
- |
|
| Stuart Iain |
Chief Scientific Officer |
• – – |
2022-03-17 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
228,879 |
|
- |
|
| Zeronda Tyler |
CFO |
• – – |
2022-03-17 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
162,329 |
|
- |
|
| Stuart Iain |
Chief Scientific Officer |
• – – |
2021-12-31 |
4 |
D |
$1.02 |
$1,275 |
D/D |
(1,250) |
153,879 |
|
- |
|
| Zeronda Tyler |
Interim CFO |
• – – |
2021-12-31 |
4 |
D |
$1.02 |
$210 |
D/D |
(206) |
87,329 |
|
- |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2021-12-31 |
4 |
D |
$1.02 |
$1,514 |
D/D |
(1,484) |
163,213 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2021-12-31 |
4 |
D |
$1.02 |
$7,025 |
D/D |
(6,887) |
760,633 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2021-11-30 |
4 |
A |
$0.88 |
$4,119 |
D/D |
4,705 |
767,520 |
|
- |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2021-09-30 |
4 |
D |
$1.39 |
$2,063 |
D/D |
(1,484) |
164,697 |
|
- |
|
| Zeronda Tyler |
Interim CFO |
• – – |
2021-09-30 |
4 |
D |
$1.39 |
$286 |
D/D |
(206) |
83,348 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2021-09-30 |
4 |
D |
$1.39 |
$18,203 |
D/D |
(13,096) |
762,815 |
|
- |
|
| Stuart Iain |
Chief Scientific Officer |
• – – |
2021-09-30 |
4 |
D |
$1.39 |
$2,057 |
D/D |
(1,480) |
155,129 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2021-09-02 |
4 |
A |
$0.00 |
$0 |
D/D |
320,312 |
775,911 |
|
- |
|
| Stuart Iain |
Chief Scientific Officer |
• – – |
2021-09-02 |
4 |
A |
$0.00 |
$0 |
D/D |
60,859 |
156,609 |
|
- |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2021-09-02 |
4 |
A |
$0.00 |
$0 |
D/D |
60,859 |
166,181 |
|
- |
|
| Zeronda Tyler |
Interim CFO |
• – – |
2021-09-02 |
4 |
A |
$0.00 |
$0 |
D/D |
60,859 |
83,554 |
|
- |
|
| Lepore Patrick G |
Director |
– • – |
2021-08-25 |
4 |
B |
$1.60 |
$20,000 |
D/D |
12,500 |
50,000 |
2.39 |
-34% |
|
| Edelman Joseph |
10% Owner |
– – • |
2021-08-16 |
4 |
S |
$1.74 |
$435,000 |
I/I |
(250,000) |
4,935,057 |
|
39% |
|
| Edelman Joseph |
10% Owner |
– – • |
2021-08-13 |
4 |
S |
$1.84 |
$460,000 |
I/I |
(250,000) |
5,185,057 |
|
37% |
|
| Edelman Joseph |
10% Owner |
– – • |
2021-08-12 |
4 |
S |
$2.23 |
$755,740 |
I/I |
(338,897) |
5,435,057 |
|
45% |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2021-06-30 |
4 |
D |
$3.51 |
$12,464 |
D/D |
(3,551) |
105,322 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2021-06-30 |
4 |
D |
$3.51 |
$66,195 |
D/D |
(18,859) |
455,599 |
|
- |
|
| Wiley Matthew T. |
Chief Commercial Officer |
• – – |
2021-06-30 |
4 |
D |
$3.51 |
$18,080 |
D/D |
(5,151) |
109,246 |
|
- |
|
| Stuart Iain |
Chief Scientific Officer |
• – – |
2021-06-30 |
4 |
D |
$3.51 |
$10,821 |
D/D |
(3,083) |
95,750 |
|
- |
|
165 Records found
|
|
Page 3 of 7 |
|
|
